Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

2 results

  • Chapter 14 - FSH versus hMG:

  • from Section 3 - Stimulation
  • Edited by Gab Kovacs, Monash University, Victoria
  • Book:
    How to Improve your ART Success Rates
    Published online:
    05 July 2011
    Print publication:
    30 June 2011, pp 75-79

  • Summary

    To compare the effectiveness of recombinant follicle stimulating hormone (rFSH) with human menopausal gonadotropin (hMG), one should make this comparison for ovulation induction then for controlled ovarian hyperstimulation in in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) cycles. This chapter compares rFSH with hMG in cryothawed cycles. A cost-effectiveness study of hMG compared to rFSH in a developing country setting was conducted which demonstrated that hMG is more cost-effective than rFSH. The cost saving using highly purified (HP)-hMG remained after varying model parameters in a probabilistic sensitivity analysis. Recently a long acting rFSH, corifollitropin alfa, has been proposed to be a suitable substitution for daily rFSH administration in women undergoing controlled ovarian stimulation in IVF/ICSI cycles. hMG and rFSH have been used to improve sperm parameters in idiopathic male infertility with the goal of increasing pregnancy rates.